Modality
mAb
MOA
KIF18Ai
Target
BCL-2
Pathway
Sphingolipid
Parkinson'sHeart FailureNMOSD
Development Pipeline
Preclinical
Feb 2023
→ Nov 2028
PreclinicalCurrent
NCT06780045
1,028 pts·Heart Failure
2024-06→2025-11·Not yet recruiting
NCT07604389
384 pts·Heart Failure
2023-02→2028-11·Not yet recruiting
1,412 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-085mo agoInterim· Heart Failure
2028-11-182.6y awayInterim· Heart Failure
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Not yet…
Preclinical
Not yet…
Catalysts
Interim
2025-11-08 · 5mo ago
Heart Failure
Interim
2028-11-18 · 2.6y away
Heart Failure
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06780045 | Preclinical | Heart Failure | Not yet recr... | 1028 | Mayo |
| NCT07604389 | Preclinical | Heart Failure | Not yet recr... | 384 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 |